Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
Condition: Diffuse Large B-Cell Lymphoma · Follicular Lymphoma · Sponsor: Genmab
About this study
The purpose of this trial is to measure the safety and effectiveness of epcoritamab (EPKINLY™), either by itself or together with other therapies, when treating participants with B-cell non-Hodgkin Lymphoma (B-NHL). The aim of the first part of the trial is to identify the most appropriate dose of epcoritamab, and the aim of the second part of the trial is to assess the selected epcoritamab dose in a larger group of participants with B-NHL. All participants in this trial will receive either epcoritamab alone, or epcoritamab combined with another standard treatment regimen, with a total of 10 different treatment arms being studied. Trial details include: * The treatment duration for each participant depends upon which arm of treatment they are assigned to. * The visit frequency for each participant depends upon which arm of treatment they are assigned to, but will be weekly to start for all participants, then will decrease to either: every 2 weeks, or every 3 weeks, or every 4 weeks, or every 8 weeks. * All participants will receive active drug; no one will be given placebo. Participants who receive treatment with epcoritamab will have it injected right under the skin. Participants will receive a different regimen of epcoritamab depending upon which arm of treatment they are assigned. Participants who receive standard treatments will have intravenous (IV) infusions and/or oral administration of those treatments. Participants will receive a different standard treatment regi…
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (57)
| University of Alabama at Birmingham | Birmingham, Alabama, United States | — |
| Cedars-Sinai Medical Center | Los Angeles, California, United States | — |
| David Geffen School of Medicine at UCLA | Los Angeles, California, United States | — |
| University of California San Francisco | San Francisco, California, United States | — |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | — |
| University of Michigan Comprehensive Cancer Center Michigan Medicine | Ann Arbor, Michigan, United States | — |
| Hackensack University Medical Center | Hackensack, New Jersey, United States | — |
| Mount Sinai | New York, New York, United States | — |
| Memorial Sloan Kettering CC | New York, New York, United States | — |
| Levine Cancer Center | Charlotte, North Carolina, United States | — |
| Southwestern Medical Center | Dallas, Texas, United States | — |
| Austin Health | Heidelberg, Australia | — |
+ 45 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04663347